Celebrating 20 years of innovation - Discover how we've been a catalyst for regional growth and UK innovation for over two decades in CPI's Annual Review 2023-2024.

SPRINT Project

Support with your novel biological product
Eligibility Cambridgeshire and Peterborough Combined Authority
Asif Tulah

Asif Tulah

Business Development Manager

Connect
Funded by

Are you looking for support with your novel therapy?

CPI is delivering a new ERDF Project, SPRINT (Supporting Process Innovation for Novel Therapies) across the Cambridge and Peterborough Combined Authority (CPCA) LEP Region to support and accelerate the commercialisation of Novel Biological Instrumentation, Products, and Therapeutics.

Using CPIs expertise, the project offers

CPI is an experienced partner supporting your path to commercialisation, through this ERDF funded programme, giving you access to business services, product and process development assets and expertise, as well as access to our state-of-the-art Biologics facilities

CPI can support many different aspects of biological product development. Some examples project types that the CPI’s SPRINT ERDF programme can support are:

Scale-up and Optimisation of established lab scale manufacturing processes in preparation for transfer to a commercial manufacturing site. This can include synthesis from the upstream process development and purification during downstream process development. 

Lab Scale Demonstration for production of lead candidates from upstream manufacturing at lab scale to provide material for further development studies and testing. 

Scale-up Evaluation of lead candidates to evaluate which potential candidate would be the easiest to manufacture and to highlight any technical issues which maybe experienced during scale up.

Analytical Method Development for a biologic product for quality control purposes which can be used to ensure a products CQA during manufacturing.

Formulation Development of a new biological product to make it commercially viable to ensure the product and the active ingredient must remain stable up to the point of use and CQAs are maintained. 

Stability and Forced Degradation of biological product to understand how the product break down to select suitable analytical techniques for measuring the products CQA, establish the shelf life of a product and evaluate potential formulation candidates. 

  • Business Support — Initial innovation clinics/​Workshops to provide initial advice, support, and signposting to relevant business support mechanisms 
  • Equipment — Specialist assets for the development of (bio)pharmaceutical production processes and analysis of (bio)pharmaceutical products 
  • Technical Expertise — Product development planning to develop scalable production processes that will meet GMP standard

Eligibility

Are you a Small/​Medium sized enterprises (SMEs) with a registered address, located within the Cambridge and Peterborough Combined Authority (CPCA) LEP area?

  • Are you developing manufacturing for biological medicines are you working on technologies to support the manufacture of such medicines?
  • Do you have a staff head count less than 250?
  • Do you have Annual turnover less than 50 million euros or a Net Balance sheet less than 43 million euros?

If you answered YES to all those questions, the ERDF SPRINT project can help/​support your company to better understand and develop your product or process, and to overcome challenges to getting a product to commercial state.

Let’s innovate together

Contact Us
Start Date: 01 Apr 2021 End Date: 30 Jun 2023 Project No. 13R20P04106
CPI is your innovation partner to make your ideas a reality.